India Pharma Outlook Team | Wednesday, 01 July 2026
India has earned global recognition for its India pharma industry, but the next phase of growth could depend on a major shift.
Experts believe the country's future lies in drug innovation through forward engineering, rather than relying mainly on generic medicines.
While India continues to be known as the "Pharmacy of the World," industry leaders say it is time to move from copying existing drugs to creating new ones. This transition could help the India pharma industry strengthen its global position, build intellectual property, and unlock long-term growth.
The discussion comes at a time when India remains one of the world's largest suppliers of affordable medicines. However, experts argue that manufacturing strength alone will not be enough to compete in the next era of global healthcare. Greater focus on pharmaceutical innovation and research and development is now seen as the key to sustained success.
India's pharmaceutical sector has built its global reputation by producing high-quality and affordable generic medicines. This approach, known as reverse engineering, helped the country meet healthcare needs across the world while making medicines more accessible.
However, industry experts believe that the next growth phase should focus on forward engineering, where companies invest in new drug discovery, original research, and advanced therapies instead of developing alternatives to existing medicines.
The country already has a strong manufacturing ecosystem, experienced scientists, and a growing biotechnology sector. By combining these strengths with higher investment in innovation, India has the potential to become a global center for pharmaceutical research.
Also Read: E-pharmacy in India 2026: Top Apps for Medicine Delivery
Despite its manufacturing achievements, India's innovation output remains limited. According to industry estimates, only eight indigenous pharmaceutical innovations have reached the market since 2021. These innovations have come from companies including Zydus Lifesciences, Wockhardt, Orchid Pharma, Biocon, ImmunoACT, and ENTOD Pharmaceuticals.
Experts believe this number highlights the need for stronger support for research and development across the Indian pharmaceutical sector. Greater funding, better collaboration between industry and academic institutions, and policies that encourage innovation could help bridge this gap.
They also point out that creating original medicines not only improves healthcare outcomes but also allows companies to secure patents, generate higher-value products, and reduce dependence on innovations developed overseas.
Industry leaders say several measures can accelerate India's journey toward becoming a global pharma leader.
Key priorities include:
These steps could help India move beyond its traditional strength in generic medicine production and establish itself as a global hub for original pharmaceutical research.
The India pharma industry has already demonstrated its ability to manufacture medicines at scale and supply healthcare products to countries around the world. The next challenge is to build an ecosystem where breakthrough drugs and innovative therapies are developed within the country.
If India successfully embraces drug innovation and forward engineering, it can move beyond being the world's pharmacy to becoming one of the world's leading creators of life-saving medicines. Such a transformation would not only strengthen the country's economy but also reshape its role in the global healthcare and life sciences industry.
.jpg)
